Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 68Breast 20Plasma cell 9Thoracic 4Gastrointestinal 4Tumor-Agnostic 3Other hematologic neoplasm 3Lymphoid 3Genitourinary 3Sarcoma 2Other solid neoplasm 2Head & Neck 2Dermatologic 2NET 1Endocrine 1Classical hematology 1CNS 1

Conditions

Neoplasms 3

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × liposomal doxorubicin × Tumor-Agnostic × Clear all
NCT02483247 2023-11-14

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
165 enrolled
Tumor-Agnostic

Neoplasms

NCT01110603 2016-05-05

A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

Tesaro, Inc.

Phase 1 Terminated
12 enrolled
Tumor-Agnostic

Neoplasms

NCT01455532 2014-10-22

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Sanofi

Phase 1 Completed
59 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡